Why CBIS Could Go To $0.50 in 2018
Background on CBIS
Cannabis Science, Inc. (CBIS), a drug development subsidiary of Irvine-based Weedmaps Media, was incorporated in 1996. It was formerly known as Gulf Onshore, prior to its name change in 2009. CBIS partners with its subsidiaries in the development, production, and commercialization of phytocannabinoid-based products for the pharmaceutical industry in the U.S. The company is focused on developing medicines to treat cancer and cancer side effects, blood pressure, autism, and several other illnesses. It also manufactures and delivers specialty products for horse and pet grooming to include topical applications.
CBIS provides an online video-based MMJ educational program which includes such diverse course options as the benefits of MMJ products, horticulture, cooking, bud tending, and MMJ law.
CBIS Drug Development and Collaborations
CBIS has several drugs in the process of development:
- CS-TATI-1: intended for newly diagnosed HIV patients; treatment-experienced, but, with HIV strains resistant to drugs; and/or intolerant of other therapies available.
- CS-S/BCC-1: intended for treatment of patients with basal and squamous cell carcinomas.
- A proprietary CBD-based therapy treating neurological conditions.
The company also collaborates with IGXBio, Inc. in the development of a DNA-based immunotherapeutic drug, GenePro. CBIS has an agreement to collaborate on research with the Dana-Farber Cancer Institute and a similar collaborative agreement with Stellenbosch University to develop a drug to treat chronic pain in women with pelvic inflammatory disease, chronic prostatitis in men, and other illnesses associated with chronic pain.
Recent News and Long-Term Potential
CBIS began in 2018 with exciting new developments which have continued in the months following. In January, the company expanded its cancer portfolio to include research for the treatment of Leukemia through CBD-based therapies. In February, CBIS’s cutting edge cancer research skyrocketed, garnering more attention than 95% of the articles from Frontiers. Also in February, CBIS announced its beta launch of a high technology, state-of-the-art website for social media and education called iCannabinoid. Expected to be the premier online hub and community for all things CBD-related, the site was integrated into pharmacy openings in the beginning of March.
March brought a series of announcements of new developments for CBIS in both the non-alcoholic and alcoholic beverage industries. First, Crown Baus, who recently acquired the creator of the world’s first CBD alcoholic beverage, Cannabia, decided to partner with CBIS to distribute non-alcoholic versions of its CBD-based alcoholic beverage in the U.S. and Canada. This partnership marked CBIS’s entrance into the multi-billion dollar beverage industry in the U.S.
CBIS acquired Bottle It Inc. and, with it, a 27,000 square ft, state-of-the-art facility for bottling energy drinks, a variety of waters, vitamin shots, sprays, tincture bottles and food containers of various sizes.
With such promising developments in a short period of time and across several industries, the company is showing immense potential for long-term growth.